有投资者向君实生物提问, 董秘,您好,作为国内首批上市的PD-1四小龙,百济神州已宣布2025年实现盈利,公司预告24年大幅度缩减亏损,公司预计25年能实现盈利吗?如果不能,公司有预计扭亏为盈的计划时间表吗?公司回答表示,投资人您好,公司正在积极推进药物研发、优化业务结构、提升运营效率、拓展市场渠道,同时也在持续加强成本控制与内部管理,为未来公司扭亏为盈创造条件。公司具体业绩情况请以公司定期报告...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.